和黄医药（中国）有限公司（股票代码：00013）于2026年5月4日发布了截至2026年4月30日的股份变动月报表。报告显示，公司法定股本保持在1,500,000,000股普通股，每股面值USD 0.1，对应法定股本总额USD 150,000,000，较上月底无变化。
本月已发行股份（不含库存股）由上月末的872,327,620股增加至872,335,120股，变动量为增发7,500股。公司披露，该增发股份系根据2015年4月24日有条件采纳的认股权计划行使期权所致，行使期权所得款项合计为USD 18,765。期末公司并无出售或转让库存股份的行为。
截至4月30日，和黄医药已确认满足香港联交所要求的公众持股量，目前股本规模稳定，普通股法定及注册股本无变化。本次公告由公司非执行董事兼公司秘书施熙德签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.